Local choices on price, contracting and affordability can each be sound and still leave a launch weaker than its assets deserve. The gap usually has nothing to do with weak work inside one team. It comes from the lack of a clear systems access strategy, one that shows how those choices interact across payers, patients, channels and policy over the whole commercial life of a product.

Senior leaders in health economics, market access and pricing need that wider view if reimbursement decisions and long-term value are to hold together. Standard cost-effectiveness and budget-impact models often miss the same interactions that commercial teams overlook.

Why strong functions still miss the bigger outcome

Pricing teams set ranges based on comparators. Contracting teams weigh access against rebate pressure. Affordability programmes track starts, abandonment and persistence. Each step can look rational against its own scorecard.

In practice, the eligible population is frequently estimated differently within the same brand, so pricing, access tactics and support design start from different foundations. Annual planning cycles, each with its own owners and data cuts, move more slowly than the market they are meant to govern. A tighter utilisation rule can hit an affordability scheme within a quarter, while a launch price agreed for the first negotiation can shape contracting room for years. Without a shared model of how these dynamics interact, the organisation cannot see the combined effect, and so cannot correct it.

The deferred cost of early trade-offs

Optimising one part of the system often shifts cost to another. Preferred formulary placement at launch may require deep concessions. A high list price paired with heavy rebates can secure early coverage and uptake, but it can compress net revenue and create exposure under Medicaid best-price rules. Recent policy overlays, including the Inflation Reduction Act and most-favoured-nation mechanisms, add further variables that a single launch decision now has to carry.

The full effect can stay hidden for nine to twelve months, then show up in another function’s results, where it is misread as poor execution when it is really the logical result of an earlier choice. Because original assumptions are rarely reopened, the same pattern repeats from one launch to the next. Health economics teams that cannot trace outcomes back to the decisions behind them lose the chance to improve future pricing strategies and budget-impact forecasts.

Syenza’s modelling of MFN-style feedback loops illustrates the point. When US payment rules reference the lowest-priced high-income markets, the ratio of modelled Medicare savings to annual sales in the binding reference country frequently exceeds 1, and for a large share of products exceeds the entire annual sales volume of that country. Cost-effectiveness and budget-impact models built on a single expected European launch date therefore understate both the risk of delayed or withheld entry and the downstream effect on US net price. Explicit launch-timing and list-price scenarios are therefore needed.

What a genuine systems access strategy requires

Many organisations treat better coordination as a matter of shared dashboards or a common data lake. The change that matters is what gets modelled. A sound systems access strategy maps how payers, providers, patients, channels, policy and competitors affect one another through delays, feedback loops and thresholds that most plans leave out. The main question moves from how a choice affects this year to how decisions and behaviours interact over a product life that often runs ten to fifteen years. A policy change in year six, for example, belongs inside today’s launch calculus.

Assumptions must be explicit, shared across functions and assigned to named owners. Calibration against historic analogues keeps behavioural claims grounded. On the payer side, the track record of health technology assessment reviews and reimbursement decisions across more than thirty countries supplies a practical base against which rebate and access options can be tested before anyone commits. Provider adoption patterns are then layered in so that growth curves stay realistic. Often the greatest early value comes from surfacing conflicting implications while the assumptions can still be revised, instead of chasing ever finer precision within a single scenario.

HEOR and value-dossier implications

For health economics teams the practical consequence is straightforward. Standard cohort or partitioned-survival models, and static budget-impact calculations that hold population size and treatment mix fixed, systematically understate cross-functional and multi-year feedbacks.

A systems view changes three things in the evidence package:

• Population and uptake assumptions must be stress-tested against the same shared estimates used by pricing and contracting, instead of being generated in isolation.
• Budget-impact analyses need explicit dynamic cohorts (incident versus prevalent, entry and exit) and policy-trigger scenarios instead of single-point first-year volume.
• Value dossiers should include a short set of cross-border and policy-interaction scenarios, particularly where Joint Clinical Assessment or international reference pricing can propagate one evidence or price decision across multiple markets.

Payers and HTA bodies increasingly expect submissions that show how price, access and support programmes interact over the product life, not only the acquisition cost or a conventional ICER.

Practical governance barriers

Dynamic simulation and AI-enabled model rebuilds can shorten the path from insight to action from weeks to a single day. They do not, however, remove the organisational frictions that stop models from changing decisions. The most common failure modes are:

• Unclear ownership of core assumptions (population, payer response, rebate depth, affordability leakage, policy triggers).
• Scenario overload that produces more outputs than the decision process can absorb.
• Insufficient calibration data or reluctance to revisit earlier commercial choices once they have been locked.
• Governance that still runs on annual planning cycles even when the model can update in real time.

Governance therefore has to come before any platform choice. Human judgement belongs in the workflow from the start, deciding which scenarios are worth running. Connected access, claims, patient and contract data should support continuous refresh so evidence and policy shifts update the model in calendar time, not once a year.

A minimal systems-access checklist

Before locking a launch price or rebate strategy, confirm the following:

1. Eligible population estimates are identical across pricing, access, HEOR and commercial functions.
2. Core assumptions (payer response curves, rebate depth, affordability leakage, policy triggers) are documented, owned and visible to every function that relies on them.
3. At least one scenario set tests the interaction of price, coverage breadth, net price and long-term value over years 1, 3, 6 and loss of exclusivity.
4. Budget-impact and cost-effectiveness analyses use the same population and uptake assumptions as the commercial model and include explicit policy-feedback cases.
5. The governance process can surface a conflicting implication and revise an assumption while the cost of change is still low.

What leadership should carry forward

Functional excellence will keep producing weaker launches until organisations model the interactions, delays and policy feedback that link those functions across the product lifecycle. Governance that favours decision-relevant scenarios, with shared assumptions behind it, is now a requirement for credible pricing, sustainable access and defensible long-term value.

A useful test for any leadership team: which decision taken last quarter would have come out differently with a full systems view, and what could the next launch gain once one is in place? Building this capability into routine governance, instead of treating it as an occasional analytical exercise, is the most direct route to stronger reimbursement decisions and more resilient performance across the wider health system.

Frequently Asked Questions

What is a systems access strategy?

It is a plan that maps how payers, providers, patients, channels, policy and competitors affect one another over a product’s life, so pricing, contracting and support choices are made against one shared model, not separate function scorecards.

Why do pricing and access decisions conflict?

Each function optimises its own scorecard, and the eligible population is often estimated differently within the same brand. Early trade-offs, such as deep formulary concessions, can surface years later in another function’s results.

Why do static budget-impact models understate risk?

Static calculations hold population size and treatment mix fixed. That leaves out cross-functional and multi-year feedback, such as policy triggers and delayed entry in a reference market.